The DOI matches its Crossref record; 150 of the 154 references it cites were found in a registry or an index; 45 of the 94 sources its claims cite were checked for support.
Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models
Open accessAbstract
Transgenic mouse models represent an essential tool for the exploration of Alzheimer's disease (AD) pathological mechanisms and the development of novel treatments, which at present provide only symptomatic and transient effects. While a variety of mouse models successfully reflects the main neuropathological hallmarks of AD, such as extracellular amyloid-β (Aβ) deposits, intracellular accumulation of Tau protein, the development of micro- and astrogliosis, as well as behavioral deficits, substantial neuron loss, as a key feature of the disease, seems to be more difficult to achieve. In this review, we summarize information on classic and more recent transgenic mouse models for AD, focusing in particular on loss of pyramidal, inter-, and cholinergic neurons. Although the cause of neuron loss in AD is still a matter of scientific debate, it seems to be linked to intraneuronal Aβ accumulation in several transgenic mouse models, especially in pyramidal neurons.
Overview
CoChat Summary
TL;DR
This review argues that neuron loss in Alzheimer’s disease mouse models is most consistently seen when intraneuronal Aβ accumulation is present, especially in pyramidal neurons. It also surveys interneuron and cholinergic neuron loss in APP-based models and concludes that no single mouse model captures all aspects of AD.
Key findings
- In APP/PS1KI mice, stereological quantifications showed a ~50% loss of CA1 neurons at 10 months, and ~30% loss already at 6 months, alongside intraneuronal Aβ accumulation.
- In 5xFAD mice, significant loss of cortical layer 5 neurons was confirmed at 9 and 12 months; this was essentially prevented by BACE1 gene deletion.
- In APP/Tau models, neuron loss was more pronounced: APP/Tau mice showed significantly reduced CA1 and entorhinal cortex neuron numbers, and 5xFAD/Tg30 mice showed ~25% loss of pyramidal neurons in the hippocampal CA1–CA4 area.
- Other Aβ-only models also showed marked neuron loss: TBA2.1 mice had ~30% CA1 neuron loss at 3 months and ~50% less neurons at 5 months; TBA42 mice had an ~35% loss of CA1 pyramidal neurons in aged animals.
Methods
- Narrative review of classic and newer transgenic AD mouse models, focused on neuron loss in pyramidal, interneuron, and cholinergic populations.
- Synthesizes findings from multiple transgenic lines, including APP-overexpressing, Aβ-peptide-only, APP/Tau, and triple-transgenic models.
- Main evidence comes from stereological neuron counts, immunohistochemistry for Aβ and neuronal markers, and reported behavioral/pathological phenotypes across published studies.
Limitations
- The paper states that no single mouse model mimics all relevant aspects of AD.
- It notes that the importance of intraneuronal Aβ for sporadic AD is still unclear, and that transient intraneuronal accumulations are hard to study in human post-mortem tissue.
- Evident from the text: this is a review, so its conclusions depend on heterogeneous prior studies rather than a new unified experimental dataset.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 (A) Schematic representation of mutant and wildtype (WT) human amyloid precursor protein (APP), highlighting the positions of mutations frequently used in APP transgenic mouse models of AD (modified from [7]). Cleavage by β-secretase (BACE1) initiates the generation of Aβ peptides with the liberation of the soluble sAPPβ fragment. The membrane-bound APP C-terminal fragment (β-CTF) is further cleaved by the γ-secretase complex to liberate Aβ and the APP intracellular domain (AICD). (B) Amino acid sequences and numbering of the most common Aβ variants present in transgenic AD mouse models.](https://figures.cochat.ai/paper-figures/3477f2af015146819155639ce2ad1e43/neuron-loss-in-alzheimers-disease-translation-in-transgenic-mouse-models-figure-1.jpg)

Verification
Claims the paper makes
36 Valid · 1 Not valid · 22 Not checked · 7 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Quantitative studies investigating interneuron populations in transgenic AD mouse models yielded more conclusive results, with most of the available studies reporting a loss of CR- and PV-positive interneurons in the hippocampal formation in AD transgenic mice [59,122,123,124,125,126].”
§ Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models > 4. Loss of Other Neuronal Cell Types in APP Transgenic Mice > 4.1. Loss of Interneurons in Transgenic Mouse Models Expressing Mutant APP
What the sources say
- Not checked — no full text of the sourcecites [59] Zallo, 2018, Loss of calretinin and parvalbumin positive interneurones in the hippocampal CA1 of aged Alzheimer’s disease mice, Neurosci. Lett. source
- Disputedcites [122] Albuquerque, 2015, Regional and sub-regional differences in hippocampal GABAergic neuronal vulnerability in the TgCRND8 mouse model of Alzheimer’s disease, Front. Aging Neurosci. sourceExperimental — accuracy not yet measured
The Results (page unavailable) report no significant difference in hippocampal PV-positive neurons between six-month-old TgCRND8 mice and controls, overall or in the regions examined. The Discussion (page unavailable) describes PV neurons as relatively resistant; this study did not assess hippocampal CR-positive neurons. Although it acknowledges a prior study reporting PV loss, its own findings do not support citing it as a study reporting loss of both populations. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [123] Jimenez, 2010, Calretinin interneurons are early targets of extracellular amyloid-beta pathology in PS1/AbetaPP Alzheimer mice hippocampus, J. Alzheimers Dis. source
- Not checked — no full text of the sourcecites [124] Popovic, 2008, Subfield and layer-specific depletion in calbindin-D28K, calretinin and parvalbumin immunoreactivity in the dentate gyrus of amyloid precursor protein/presenilin 1 transgenic mice, Neuroscience source
- Supportedcites [125] Takahashi, 2010, Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer’s disease, Brain Struct. Funct. source
The Discussion (Summary of results) reports age-related loss of both PV- and CR-positive hippocampal neurons in an AD transgenic/knock-in mouse model. This paper supports its use as one of the studies cited for that finding; it does not by itself establish the sentence’s count of “most” available studies. (LLM, conf=0.90)
- Supportedcites [126] Giesers, 2020, Loss of Hippocampal Calretinin and Parvalbumin Interneurons in the 5XFAD Mouse Model of Alzheimer’s Disease, ASN Neuro source
The Abstract describes several studies reporting losses of hippocampal CR- and PV-positive cells in transgenic AD mice, while acknowledging a study that found no genotype-dependent difference. The Discussion also reports losses across several mouse models. The claim says most studies, not all, and is consistent with that account. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This discrepancy to the abovementioned data in models with intraneuronal Aβ accumulation might be due to the use of APP cross-reacting antibodies (such as 6E10 or 4G8), which have been frequently used for Aβ labelling [111]. As these antibodies detect central Aβ epitopes, they usually also pick-up considerable levels of full-length APP, resulting in an overestimation of the effective intraneuronal”
§ Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models > 3. Tau Triggers Neuron Loss in Models with Aβ Pathology
What the sources say
- Partly supportedcites [111] Aho, 2010, Immunohistochemical Visualization of Amyloid-β Protein Precursor and Amyloid-β in Extra- and Intracellular Compartments in the Human Brain, J. Alzheimer’s Dis. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [112] Wirths, 2012, AbetaPP Accumulation and/or Intraneuronal Amyloid-beta Accumulation? The 3xTg-AD Mouse Model Revisited, J. Alzheimers Dis. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Interestingly, staining with Fluoro Jade C, a marker for degenerating neurons, did not reveal evidence for neurodegeneration [109] and a quantitative analysis of CA1 neuron numbers revealed a lack of neuron loss in this brain region in 3xTg mice during aging [110].”
§ Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models > 3. Tau Triggers Neuron Loss in Models with Aβ Pathology
What the sources say
- Supportedcites [109] Rohn, 2008, Lack of Pathology in a Triple Transgenic Mouse Model of Alzheimer’s Disease after Overexpression of the Anti-Apoptotic Protein Bcl-2, J. Neurosci. source
The Discussion (page unavailable) reports stereological analyses of CA1 showing no significant neuron loss in 3xTg-AD mice compared with nontransgenic mice at 3 or 20 months. The paper attributes those analyses to a personal communication rather than presenting them as its own measurements. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [110] Manaye, 2011, Age-related loss of noradrenergic neurons in the brains of triple transgenic mice, AGE source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These APP/PS1KI mice present with early intraneuronal Aβ accumulations in the CA1 region of the hippocampus, as well as in deep cortical layers (Figure 2), and stereological quantifications revealed a ~50% loss of CA1 neurons at 10 months of age [52].”
§ Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models > 2. Intraneuronal Aβ Is Linked to Pyramidal Neuron Loss in Transgenic AD Mouse Models > 2.1. Pyramidal Neuron Loss in Transgenic Mice with APP Overexpression
What the sources say
- Partly supportedcites [52] Casas, 2004, Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model, Am. J. Pathol. sourceExperimental — accuracy not yet measured
The Results report design-based stereology showing approximately 50% pyramidal-cell loss in 10-month-old APPSLPS1KI mice. The quantified field was CA1/2, however, not CA1 alone, so the cited result does not establish a separate ~50% estimate for CA1 neurons. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Nonetheless, thioflavin S-positive fibrillary Aβ deposits contribute to focal neuronal toxicity, at least in their immediate environment, as shown in both AD cases and AD transgenic mice [36]”
§ Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models > 1. Introduction
What the sources say
- Supportedcites [36] Urbanc, 2002, Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer’s disease, Proc. Natl. Acad. Sci. USA source
The Discussion (page not supplied) reports an association between ThioS-positive Aβ plaques and focal neuronal loss in both human AD brain and a transgenic mouse model, with no toxicity extending beyond the staining deposit. It concludes that fibrillar Aβ toxicity is one mechanism of neuronal death in both settings, while acknowledging that neuronal death preceding plaque formation cannot be excluded. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
17 more claims · 4 with their cited sources checked
Create a free account to see all 66 claims and every source verdict.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 3
- The quote only partly states this claim. 2
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Essential neuropathological hallmarks important for the diagnosis of AD consist of the extracellular deposition of amyloid-β (Aβ) peptides in plaques [1] and intracellular aggregation of hyperphosphorylated Tau protein in neurofibrillary tangles (NFTs) [2].”
BackgroundAmyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 1×
“Aβ42 peptides starting with phenylalanine (F) at position 4 (Aβ4–42) are among the first Aβ peptides that have been isolated from amyloid plaque cores in the human AD brain [101] and represent a highly abundant species in brains from both sporadic and familial AD cases [102].”
BackgroundTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“The role of extracellular Aβ plaques is also not entirely clear: While in early studies, a substantial relationship between plaque numbers and cognitive decline in the aging population has been assumed [32], subsequent studies challenged this observation, reporting no association [33] and allocating more importance to…”
ResultCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 4×
“Abbreviations APP Amyloid precursor protein Aβ Amyloid-β AD Alzheimer’s disease APOE Apolipoprotein E BACE1 β-site APP cleaving enzyme 1 ChAT Choline acetyltransferase CR Calretinin ER Endoplasmic reticulum FAD Familial Alzheimer’s disease HEK Human embryonic kidney KI Knock-in nbM Nucleus basalis of Meynert NFL Neuro…”
BackgroundInfluentialOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 3×
“, 5XFAD [46], APPswe/PS1dE9 [72], APP/PS1 [49], PS2APP [73], APP/PS1KI [52]), APP and Tau (such as APP/Tau [55]), or triple transgenic mice expressing APP, PS1/2, and Tau (e.”
BackgroundMethodThe neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 1×
“Essential neuropathological hallmarks important for the diagnosis of AD consist of the extracellular deposition of amyloid-β (Aβ) peptides in plaques [1] and intracellular aggregation of hyperphosphorylated Tau protein in neurofibrillary tangles (NFTs) [2].”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“Another, more recently identified risk factor is the triggering receptor expressed on myeloid cells 2 (TREM2), where genetic variants also increase SAD risk [145].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“These observations supported the amyloid cascade hypothesis and the central role of fibrillary Aβ aggregates in the etiology of the disease [10].”
Result
Cited by
Neuronal cell death mechanisms in Alzheimer’s disease: An insight
Goel, P., Chakrabarti, S., Goel, K., Bhutani, K., Chopra, T., & Bali, S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.937133 · Cited by 234
“However, the neuronal death is much less pronounced than amyloid-beta pathology or tauopathy or reactive gliosis in the brains of AD transgenic animals (Wirths and Zampar, 2020).”
BackgroundMEG3 activates necroptosis in human neuron xenografts modeling Alzheimer’s disease
Balusu, S., Horré, K., Thrupp, N., Craessaerts, K., Snellinx, A., Serneels, L., T’Syen, D., Chrysidou, I., Arranz, A. M., Sierksma, A., et al. (2023) · Science · doi:10.1126/science.abp9556 · Cited by 230
Hamzé, R., Delangre, E., Tolu, S., Moreau, M., Janel, N., Bailbé, D., & Movassat, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315287 · Cited by 158
“AD, the leading cause of dementia in the elderly [21], is a progressive neurodegenerative disease related to neuronal loss affecting the hippocampus and neocortical areas [22].”
BackgroundTransgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis
Sanchez-Varo, R. M., Mejias‐Ortega, M., Fernandez-Valenzuela, J. J., Nuñez‐Diaz, C., Cáceres-Palomo, L., Vegas‐Gomez, L., Sánchez‐Mejías, E., Trujillo‐Estrada, L., García‐León, J. A., Moreno‐González, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105404 · Cited by 142
Autophagy–lysosomal-associated neuronal death in neurodegenerative disease
Nixon, R. A. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02799-7 · Cited by 133
“…in mouse models of AD pathology that exhibit greatest intraneuronal accumulation of Aβ and/or APP-βCTF [29, 67, 81, 109, 130, 160], whether or not they develop extracellular plaques [240] or whether ß-amyloid experimentally is redistributed from extracellular to intra-cellular locations [160].”
Metadata
- Authors
- Wirths, O., & Zampar, S.
- Affiliations
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Wirths, Oliver
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-10-30
- Volume
- 21
- Issue
- 21
- Pages
- 8144
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7663280
- OpenAlex
- W3096611573
- Semantic Scholar
- c1a033ed4763bc9721a09b6c1e1442c9b037e668
- Cited by
- 75
- References
- 154
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 14 · 2023: 20 · 2022: 12 · 2021: 7 · 2020: 1
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Funders
- Gerhard Hunsmann Stiftung (T0323-28817)
- Alzheimer Forschung Initiative (16013)
- Alzheimer Stiftung Göttingen (-)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neuronal loss, transgenic mouse model, pyramidal neurons, cholinergic neurons, interneurons, intraneuronal amyloid-beta, amyloid plaques, neurodegeneration, tau pathology, astrocyte activation
- MeSH terms
- Alzheimer Disease, Animals, Humans, Mice, Transgenic, Neurons, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models. https://app.cochat.ai/papers/10.3390/ijms21218144
- The paper
- Wirths, O., & Zampar, S. (2020). Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21218144
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.